# A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents (MYCOS)

First published: 16/09/2012 Last updated: 01/04/2024



### Administrative details

#### **EU PAS number**

EUPAS2857

#### **Study ID**

35221

#### DARWIN EU® study

No

### **Study countries**

United States

### **Study description**

This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2016.

### Study status

Finalised

### Research institutions and networks

### Institutions

World Health Information Science Consultants, LLC (WHISCON)

Brigham and Women's Hospital and Massachusetts General Hospital MA, USA, Hospital of the University of Pennsylvania PA, USA, University of Pittsburgh Medical Center PA, USA, Duke University Medical Center NC, USA, University of Michigan Hospitals and Health Systems MI, USA, Johns Hopkins University MD, USA

# Contact details

### Study institution contact

Sebastian Schneeweiss Deb.Hennessey@WHISCON.com

Study contact

Deb.Hennessey@WHISCON.com

Primary lead investigator Sebastian Schneeweiss

Primary lead investigator

# Study timelines

### Date when funding contract was signed

Planned: 23/05/2011 Actual: 23/05/2011

### Study start date

Planned: 20/09/2012 Actual: 20/09/2012

### Data analysis start date Planned: 01/10/2012

Actual: 01/10/2012

Date of interim report, if expected Planned: 30/06/2014 Actual: 30/06/2014 Date of final study report Planned: 30/11/2020 Actual: 05/11/2018

# Sources of funding

• Pharmaceutical company and other private sector

### More details on funding

Astellas Pharma Europe

# Study protocol

WHISCON Antifungals Protocol 30 Aug 2011 Amendment 19 July 2012 for ENCEPP posting.pdf(1.12 MB)

9463-cl-1401-clp-05-reissue-v3dot1-en-final-02.pdf(1.95 MB)

# Regulatory

### Was the study required by a regulatory body?

Yes

**Is the study required by a Risk Management Plan (RMP)?** EU RMP category 2 (specific obligation of marketing authorisation)

# Other study registration identification numbers and links

### Methodological aspects

### Study type

# Study type list

**Study topic:** Human medicinal product

#### Study type:

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

### Data collection methods:

Secondary use of data

#### Main study objective:

This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2016.

### Study Design

### Non-interventional study design

Cohort

# Study drug and medical condition

### Anatomical Therapeutic Chemical (ATC) code (D01B) ANTIFUNGALS FOR SYSTEMIC USE ANTIFUNGALS FOR SYSTEMIC USE

# Population studied

### Short description of the study population

Patients were identified by their first PAF use during a hospitalization between January 1, 2005 and December 31, 2012.

All exclusions were applied to create a single study population for analyses. Patients were excluded if they had earlier recorded PAF use, if they started use of micafungin and a different PAF on the same day, had pre-existing chronic hepatic or renal disease, had both no ALT and no AST or had no bilirubin or had no serum creatinine test results recorded in the 30 days prior to and including PAF initiation. Patients were removed if their last preceding AST or ALT in the 30 days prior to and including PAF initiation were more than five times the local upper limit of normal (ULN), or if their last ALT value was greater than 300 U/L, or if their last AST was greater than 200 U/L, or if their last preceding bilirubin was more than three times the local ULN. Patients were required to have no record of having received dialysis in the 30 days prior to and including cohort entry.

Patients were excluded from the cohort if their last preceding eGFR was <30 ml/min in the 30 days prior to and including PAF initiation. Patients were also

excluded if they had no bilirubin, creatinine, or neither ALT nor AST during follow-up.

### Age groups

Preterm newborn infants (0 – 27 days) Term newborn infants (0 – 27 days) Infants and toddlers (28 days – 23 months) Children (2 to < 12 years) Adolescents (12 to < 18 years) Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

#### **Special population of interest**

Immunocompromised

#### **Estimated number of subjects**

35000

# Study design details

#### Outcomes

Three 30-day outcomes (a, b, and c) and one long-term outcome (d) identified during up to 12 years following treatment. a. Treatment-emergent hepatic injury or dysfunctionb. Treatment-emergent renal failure or dysfunctionc. Rehospitalization for the parenteral treatment of fungal infectionsd. Death from hepatocellular carcinoma (HCC)

### Data analysis plan

Study outcomes will be identified in the short term (up to 30 days) and the long term (up to 12 years).Survival analysis will compare the occurrence of each 30day outcome among the parenteral antifungal agents and will employ multivariate propensity score methods to adjust for possible confounding effects of age, gender, race, and comorbid conditions . A further assessment of potential for residual effects due to patient characteristics obtained through chart review of cases and a random sample of the cohort will be conducted. The occurrence of the long-term outcome (HCC mortality) will analogously employ survival analysis and propensity score techniques.

### Documents

#### **Study results**

9463-cl-1401-clrr-09-disc01-en-final-03.pdf(1.7 MB)

#### **Study publications**

Schneeweiss S, Carver PL, Datta K, et al. Short-term risk of liver and renal in... Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Letourneau AR, Marty F,...

### Data management

# **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

### Data sources (types)

Administrative healthcare records (e.g., claims) Drug dispensing/prescription data Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

### Data characterisation conducted

No